CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Regulation FD disclosure
- 4 Option exercise Director acquired 2,406 shares (option exercise)
- 144 Insider Sale of Securities
- 4 Grant or award CLO & Secretary acquired 6,415 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 5,000 shares at $115.03 ($575,149)
- 4 Grant or award Chief Executive Officer acquired 21,382 shares (grant or award)
- 144 Insider Sale of Securities
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Material agreement · Regulation FD disclosure
- 4 Shares withheld for taxes Chief Executive Officer gave up 13,452 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 9,587 shares (to pay taxes)
- 4 Shares withheld for taxes CLO & Secretary gave up 6,523 shares (to pay taxes)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale Chief Financial Officer sold 2,104 shares at $116.37 ($244,850)
- 144 Insider Sale of Securities
- 4 Shares withheld for taxes Chief Financial Officer gave up 1,859 shares (to pay taxes)
Page 10 of 115 · 2,300 filings